Annual report pursuant to Section 13 and 15(d)

ACCRUED EXPENSES

v3.24.0.1
ACCRUED EXPENSES
 12 Months Ended
Dec. 31, 2023
Payables and Accruals [Abstract]  
ACCRUED EXPENSES
10.
ACCRUED EXPENSES

Accrued expenses consisted of the following:

 

 

 

December 31,
2023

 

 

December 31,
2022

 

 

 

 

 

 

 

 

Accrued pre-clinical and clinical costs

 

$

6,274,188

 

 

$

2,137,317

 

Accrued product development costs

 

 

745,447

 

 

 

247,500

 

Accrued compensation

 

 

2,325,488

 

 

 

2,224,951

 

Accrued administrative costs

 

 

343,285

 

 

 

473,376

 

Accrued interest

 

 

1,342,098

 

 

 

916,108

 

Total

 

$

11,030,506

 

 

$

5,999,252